Welcome to our dedicated page for Citius Oncology news (Ticker: CTOR), a resource for investors and traders seeking the latest updates and insights on Citius Oncology stock.
Citius Oncology, Inc. (CTOR) delivers innovative targeted therapies for challenging cancers, with its flagship treatment LYMPHIR® leading advancements in cutaneous T-cell lymphoma care. This news hub provides investors and medical professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Access timely reports on FDA communications, trial data publications, and commercialization progress. Our curated collection features verified press releases covering therapeutic approvals, research collaborations, and intellectual property developments. Track updates on combination therapy trials, market expansion strategies, and peer-reviewed study outcomes.
Key content includes analysis of NCCN guideline inclusions, HCPCS coding updates affecting reimbursement, and manufacturing scale-up announcements. Stay informed about LYMPHIR's evolving clinical applications and pipeline expansion into new oncologic indications through primary-source documentation.
Bookmark this page for direct access to CTOR's official communications, including financial results presentations and executive commentary on treatment adoption rates. Regular updates ensure you maintain current awareness of this innovative biopharma company's trajectory in immuno-oncology.
Citius Oncology (Nasdaq: CTOR) signed a U.S. distribution services agreement with McKesson (NYSE: MCK) to serve as an authorized distributor of record for LYMPHIR (denileukin diftitox-cxdl).
LYMPHIR is FDA approved for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy. The McKesson agreement completes Citius Oncology's core U.S. distribution network with all three largest pharmaceutical wholesalers, supporting the planned commercial launch in Q4 2025. The company also cites inventory readiness, permanent J-code J9161, NCCN guideline inclusion, and provider and patient education resources as part of its commercialization preparations.
Citius Pharmaceuticals (Nasdaq: CTXR) and Citius Oncology (Nasdaq: CTOR) announced management participation in three investor conferences in October 2025. CTXR management will attend LD Micro Main Event XIX (Oct 19-21, 2025) in San Diego and the Think Equity Conference (Oct 30, 2025) in New York. CTOR management will attend the 2025 Maxim Growth Summit (Oct 22-23, 2025) in New York.
Both companies said investors may request 1-on-1 meetings via the event platforms or by contacting the companies' investor relations teams; CTOR noted scheduled meetings with institutional investors and Maxim senior analysts.
Citius Oncology (Nasdaq: CTOR) finalized an exclusive Master Service Agreement with EVERSANA to support the planned U.S. commercialization of LYMPHIR™ (denileukin diftitox-cxdl) in Q4 2025. EVERSANA will provide an integrated suite of pre- and post-launch services including medical information, pharmacovigilance, revenue cycle management, program management, data and analytics, and channel management. LYMPHIR was approved by the U.S. FDA in August 2024 for relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy. The agreement is exclusive and intended to scale launch operations and market access for LYMPHIR in the United States.
Citius Oncology (Nasdaq: CTOR) announced on October 7, 2025 that it is expanding international access to LYMPHIR™ (denileukin diftitox-cxdl) via country-specific Named Patient Programs (NPPs) in Europe, South America and the Middle East.
The company signed an exclusive distribution agreement with Integris Pharma S.A., headquartered in Athens, to cover Greece, Cyprus, Malta, Bulgaria, Romania, Croatia, Serbia, Albania, Bosnia Herzegovina, Kosovo, Montenegro and North Macedonia. NPPs provide early patient access prior to full marketing authorization and do not constitute commercial approval outside the U.S.
Citius Oncology (NASDAQ: CTOR) has successfully closed its previously announced financing round, consisting of a registered direct offering and concurrent private placement. The company raised $9.0 million in gross proceeds through the sale of 5,142,858 shares of common stock and warrants at a combined price of $1.75 per share.
The offering included unregistered warrants to purchase up to 5,142,858 additional shares at an exercise price of $1.84 per share. These warrants will become exercisable after six months and expire five and a half years from issuance. Maxim Group LLC served as the sole placement agent for the transaction.
Citius Oncology (NASDAQ:CTOR) has announced a $9.0 million registered direct offering and concurrent private placement. The company will issue 5,142,858 shares of common stock at a combined effective price of $1.75 per share to a single institutional investor.
The deal includes unregistered warrants to purchase an additional 5,142,858 shares at an exercise price of $1.84 per share. These warrants will be exercisable after six months and expire 5.5 years from issuance. The offering is expected to close around September 10, 2025, with Maxim Group LLC serving as the sole placement agent.
Citius Oncology (NASDAQ:CTOR) has announced the deployment of a proprietary AI platform to enhance its commercial team's performance ahead of the anticipated LYMPHIR™ launch for cutaneous T-cell lymphoma (CTCL) treatment. The platform leverages advanced data analytics and machine learning to identify potential LYMPHIR candidates and optimize healthcare provider engagement.
The AI system analyzes treatment patterns and diagnosis data to support targeted prescriber outreach. It features a continuous learning model that integrates real-world U.S. claims data and marketing performance analytics to deliver predictive insights and enable personalized customer engagement across digital and in-person channels.
Citius Oncology (NASDAQ:CTOR) reported its fiscal Q3 2025 results and provided updates on its commercial launch preparations for LYMPHIR™, a novel therapy for cutaneous T-cell lymphoma. The company secured $12.5 million in financing during Q3, with an additional $9 million raised in July 2025, to support LYMPHIR's market introduction planned for Q4 2025.
Financial results showed a net loss of $5.4 million ($0.08 per share), compared to $4.8 million ($0.07 per share) in Q3 2024. R&D expenses decreased to $938,000 from $1.1 million year-over-year, while G&A expenses increased to $1.9 million from $1.5 million. The company reported $112 in cash with 71,552,402 common shares outstanding as of June 30, 2025.
Citius Oncology (NASDAQ:CTOR) has successfully closed its public offering, raising approximately $9.0 million in gross proceeds. The offering consisted of 6,818,182 shares of common stock and warrants at a public offering price of $1.32 per share.
The warrants are immediately exercisable at $1.32 per share and will expire in five years. The company plans to use the proceeds primarily to support the commercialization of LYMPHIR, including milestone and royalty payments, as well as for working capital and general corporate purposes. Maxim Group LLC served as the sole placement agent for this "reasonable best-efforts" offering.
Citius Oncology (NASDAQ:CTOR) has announced the pricing of a public offering to raise $9.0 million through the sale of 6,818,182 shares of common stock and warrants at $1.32 per share. The warrants will have the same exercise price, be immediately exercisable, and expire in five years.
The company plans to use the proceeds primarily for the commercialization of LYMPHIR, including milestone and royalty payments, as well as working capital. The offering, managed by Maxim Group LLC as sole placement agent, is expected to close around July 17, 2025.
FAQ
What is the current stock price of Citius Oncology (CTOR)?
What is the market cap of Citius Oncology (CTOR)?
